Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) have been given a consensus rating of “Buy” by the twelve ratings firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $14.75.
Several research firms have issued reports on MRTX. BidaskClub upgraded shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. ValuEngine upgraded shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. HC Wainwright upped their target price on shares of Mirati Therapeutics from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Oppenheimer set a $18.00 target price on shares of Mirati Therapeutics and gave the company a “buy” rating in a research note on Monday, January 8th. Finally, Cann restated a “buy” rating and set a $18.00 target price on shares of Mirati Therapeutics in a research note on Monday, January 8th.
In other news, SVP Jamie Christensen sold 10,814 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $27.00, for a total value of $291,978.00. Following the transaction, the senior vice president now owns 13,691 shares in the company, valued at approximately $369,657. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 61,039 shares of company stock worth $1,646,881 in the last quarter. Company insiders own 5.10% of the company’s stock.
Mirati Therapeutics (NASDAQ:MRTX) traded up $0.35 on Tuesday, reaching $28.70. 320,888 shares of the company’s stock traded hands, compared to its average volume of 422,823. The company has a market cap of $774.73, a PE ratio of -9.23 and a beta of 2.17. Mirati Therapeutics has a 1-year low of $2.70 and a 1-year high of $30.50.
ILLEGAL ACTIVITY NOTICE: “Mirati Therapeutics, Inc. (MRTX) Receives Average Rating of “Buy” from Brokerages” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3222027/mirati-therapeutics-inc-mrtx-receives-average-rating-of-buy-from-brokerages.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company?s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.